RecruitingPhase 2ketamine

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

Sponsored by Sam Tyagi

NCT ID
NCT04600089
Target Enrollment
30 participants
Start Date
2020-12-08
Est. Completion
2027-08

About This Study

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

Conditions Studied

Descending Aortic DissectionPostoperative PainThoracoabdominal Aortic Aneurysm

Interventions

  • Saline
  • Ketamine

Eligibility

Age:18 Years - 90 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* willing to give informed consent
* scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair
* requires naloxone continuous infusion for spinal prophylaxis

Exclusion Criteria:

* allergy to ketamine, acetaminophen, or fentanyl
* diagnosis of schizophrenia
* history of hydrocephalus or central nervous system mass
* incarcerated individuals
* pregnant or lactating individuals

Study Locations (1)

University of Kentucky Medical Center
Lexington, Kentucky, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Eric Johnson, PharmD
CONTACT
8593235722eric.johnson@uky.edu
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source